Generic drugmaker Granules India is foraying into the peptide segment and contract development and manufacturing organisation (CDMO) business with a ₹192.5 crore (CHF 20 million) acquisition of Swiss firm Senn Chemicals AG.
Founded in 1963 and headquartered in Dielsdorf, Switzerland, Senn is focused on custom peptide manufacturing and supports global clients across pharmaceuticals, cosmetics and theragnostic industries, from early development to commercial production. The closing of the acquisition is subject to certain conditions and expected in first half of 2025, Granules said in a filing on Friday.
The acquisition brings Senn’s expertise in Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), along with a strong CDMO business and established customer relationship. It will enable Granules acquiring capabilities into high-growth peptide-based therapeutics and aligns with its vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market, including Glucagon-like peptide-1 (GLP-1) receptor agonists and other next-generation therapeutics.
Granules and Senn are developing two GLP-1 based active pharmaceutical ingredients, and both the projects are progressing well, and more peptide-based APIs are planned to be added in the portfolio, to be developed using Senn’s R&D capabilities, the Hyderabad-based firm said.
With this acquisition, Granules will leverage Senn’s European presence and innovation-driven peptide platform to accelerate its CDMO expansion and meet the fast-growing demand for Amino Acid Derivative (AAD), peptide fragments, and peptide-based therapeutics.
“The acquisition marks a significant milestone … by entering the rapidly growing peptide therapeutics segment and acquiring CDMO capabilities, we are expanding into next-generation therapeutics. Senn’s expertise in peptide synthesis coupled with our large-scale, cost-efficient manufacturing capabilities, positions us to deliver high-quality peptide-based solutions globally,” Granules CMD Krishna Prasad Chigurupati said.
Published – February 22, 2025 09:04 pm IST
